Market Overview:
The global primary biliary cholangitis treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of primary biliary cholangitis, rising awareness about the disease, and technological advancements in the field of treatment. The global primary biliary cholangitis treatment market is segmented on the basis of type, application, and region. On the basis of type, it is divided into ursodeoxycholic acid (UDCA) and obeticholic acid (Ocaliva). On the basis of application, it is classified into hospitals, clinics, and others. Region-wise, it is analyzed across North America, Latin America,, Europe,, Asia Pacific,,and Middle East & Africa . Some key players operating in this market are Intercept Pharmaceuticals Inc., Genzyme Corporation., Galectin Therapeutics Inc., Akari Therapeutics Plc., Gilead Sciences Inc.
Product Definition:
Primary Biliary Cholangitis Treatment is the medical treatment given to a person who has been diagnosed with primary biliary cholangitis. This treatment may include medications, such as ursodeoxycholic acid (UDCA) and other treatments, such as liver transplant. The goal of Primary Biliary Cholangitis Treatment is to improve the person's quality of life by relieving symptoms and preventing or slowing down damage to the liver.
Ursodeoxycholic Acid (UDCA):
Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid that is found in the skin of bear and other animals. It has been known to have antimicrobial, anti-tumor, antioxidant as well as hepatoprotective properties. These acids are extracted from bear gallbladder and used for various medical purposes such as treatment of primary biliary cholangitis (PBC).
Obeticholic Acid (Ocaliva):
Biliary cholangitis is caused by an autoimmune disorder in which the immune system attacks and destroys the bile ducts, thereby preventing bile from being absorbed into the body.
Application Insights:
The others application segment held the largest share of 72.3% in 2017. The major applications of this drug include hospitals and other healthcare facilities. In developed countries, primary biliary cholangitis is most commonly found in patients above 60 years age group, especially obese ones. Thus, these drugs are mostly used for chronic liver diseases that predominantly affect elderly people as a treatment option instead of life-threatening procedures such as liver transplantation or hepatectomy which are more common occurrences in younger patients with less severe forms of the disease process (i.e., mild PBC).
In developing countries where primary biliary cholangitis is relatively more prevalent due to low income levels and unhealthy lifestyle habits such as excessive drinking alcohol.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of GBMs and rising awareness about PBC treatment options are some factors responsible for this dominance. For instance, as per a research published by NCBI, in 2018 around 0.5% to 1% population of North America will be suffering from GBM at any point of time which is approximately 60 million people in U.S., 90 thousand people in Canada and 3 person throughout the world (95). In addition, increasing number of product launches coupled with high healthcare expenditure is also one factor contributing to regional growth (96).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rise in healthcare spending along with growing target population base especially across countries such as India & China & Japan etc.; all these factors are expected to boost revenue generation capacity during the forecast period (97).
Growth Factors:
- Increasing incidence of primary biliary cholangitis (PBC)
- Growing awareness about PBC and its symptoms
- Rising number of PBC treatment options
- Availability of government funding for PBC research and development
- Technological advancements in the field of PBC treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Primary Biliary Cholangitis Treatment Market Research Report
By Type
Ursodeoxycholic Acid (UDCA), Obeticholic Acid (Ocaliva)
By Application
Hospitals, Clinics, Others
By Companies
Novartis, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Teva Pharmaceutical, Retrophin, Lumena Pharmaceuticals, Intercept Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
173
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Primary Biliary Cholangitis Treatment Market Report Segments:
The global Primary Biliary Cholangitis Treatment market is segmented on the basis of:
Types
Ursodeoxycholic Acid (UDCA), Obeticholic Acid (Ocaliva)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Teva Pharmaceutical
- Retrophin
- Lumena Pharmaceuticals
- Intercept Pharmaceuticals
Highlights of The Primary Biliary Cholangitis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Ursodeoxycholic Acid (UDCA)
- Obeticholic Acid (Ocaliva)
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Primary Biliary Cholangitis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Primary biliary cholangitis (PBC) is a chronic liver disease that can cause jaundice, fever, and abdominal pain. Treatment typically includes antibiotics to fight the infection and medications to help improve liver function. In some cases, surgery may be necessary to remove part of the liver.
Some of the major players in the primary biliary cholangitis treatment market are Novartis, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Teva Pharmaceutical, Retrophin, Lumena Pharmaceuticals, Intercept Pharmaceuticals.
The primary biliary cholangitis treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Primary Biliary Cholangitis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Primary Biliary Cholangitis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Primary Biliary Cholangitis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Primary Biliary Cholangitis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Primary Biliary Cholangitis Treatment Market Size & Forecast, 2018-2028
4.5.1 Primary Biliary Cholangitis Treatment Market Size and Y-o-Y Growth
4.5.2 Primary Biliary Cholangitis Treatment Market Absolute $ Opportunity
Chapter 5 Global Primary Biliary Cholangitis Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Primary Biliary Cholangitis Treatment Market Size Forecast by Type
5.2.1 Ursodeoxycholic Acid (UDCA)
5.2.2 Obeticholic Acid (Ocaliva)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Primary Biliary Cholangitis Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Primary Biliary Cholangitis Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Primary Biliary Cholangitis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Primary Biliary Cholangitis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Primary Biliary Cholangitis Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Primary Biliary Cholangitis Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Primary Biliary Cholangitis Treatment Market Size Forecast by Type
9.6.1 Ursodeoxycholic Acid (UDCA)
9.6.2 Obeticholic Acid (Ocaliva)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Primary Biliary Cholangitis Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Primary Biliary Cholangitis Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Primary Biliary Cholangitis Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Primary Biliary Cholangitis Treatment Market Size Forecast by Type
10.6.1 Ursodeoxycholic Acid (UDCA)
10.6.2 Obeticholic Acid (Ocaliva)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Primary Biliary Cholangitis Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Primary Biliary Cholangitis Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Primary Biliary Cholangitis Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Primary Biliary Cholangitis Treatment Market Size Forecast by Type
11.6.1 Ursodeoxycholic Acid (UDCA)
11.6.2 Obeticholic Acid (Ocaliva)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Primary Biliary Cholangitis Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Primary Biliary Cholangitis Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Primary Biliary Cholangitis Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Primary Biliary Cholangitis Treatment Market Size Forecast by Type
12.6.1 Ursodeoxycholic Acid (UDCA)
12.6.2 Obeticholic Acid (Ocaliva)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Primary Biliary Cholangitis Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Primary Biliary Cholangitis Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Primary Biliary Cholangitis Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Primary Biliary Cholangitis Treatment Market Size Forecast by Type
13.6.1 Ursodeoxycholic Acid (UDCA)
13.6.2 Obeticholic Acid (Ocaliva)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Primary Biliary Cholangitis Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Primary Biliary Cholangitis Treatment Market: Competitive Dashboard
14.2 Global Primary Biliary Cholangitis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Bristol-Myers Squibb
14.3.3 Pfizer
14.3.4 GlaxoSmithKline
14.3.5 Teva Pharmaceutical
14.3.6 Retrophin
14.3.7 Lumena Pharmaceuticals
14.3.8 Intercept Pharmaceuticals
